Cargando…

Immune function biomarker QuantiFERON-monitor is associated with infection risk in cirrhotic patients

AIM: To investigate whether a novel immune function biomarker QuantiFERON-Monitor (QFM) can identify cirrhotic patients at greatest risk of infection. METHODS: Adult cirrhotic patients on the liver transplant waiting list were recruited for this observational cohort study from a tertiary liver trans...

Descripción completa

Detalles Bibliográficos
Autores principales: Sood, Siddharth, Yu, Lijia, Visvanathan, Kumar, Angus, Peter William, Gow, Paul John, Testro, Adam Gareth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5165271/
https://www.ncbi.nlm.nih.gov/pubmed/28050238
http://dx.doi.org/10.4254/wjh.v8.i35.1569
_version_ 1782482801680973824
author Sood, Siddharth
Yu, Lijia
Visvanathan, Kumar
Angus, Peter William
Gow, Paul John
Testro, Adam Gareth
author_facet Sood, Siddharth
Yu, Lijia
Visvanathan, Kumar
Angus, Peter William
Gow, Paul John
Testro, Adam Gareth
author_sort Sood, Siddharth
collection PubMed
description AIM: To investigate whether a novel immune function biomarker QuantiFERON-Monitor (QFM) can identify cirrhotic patients at greatest risk of infection. METHODS: Adult cirrhotic patients on the liver transplant waiting list were recruited for this observational cohort study from a tertiary liver transplant referral unit. The immune function biomarker, QFM was performed using the same method as the widely available Quantiferon-gold assay, and measures output in interferon gamma in IU/mL after dual stimulation of the innate and adaptive immune systems. Ninety-one cirrhotic patients were recruited, with 47 (52%) transplanted on the day of their QFM. The remaining 44 (48%) were monitored for infections until transplant, death, or census date of 1(st) February 2014. RESULTS: Cirrhotic patients express a median QFM significantly lower than healthy controls (94.5 IU/mL vs 423 IU/mL), demonstrating that they are severely immunosuppressed. Several factors including model for end stage liver disease, presence of hepatocellular carcinoma, bilirubin, international normalized ratio and haemoglobin were associated with QFM on univariate analysis. Disease aetiology did not appear to impact QFM. On multivariate analysis, only Child-Pugh score and urea were significantly associated with a patient’s immune function as objectively measured by QFM. In the 44 patients who were not transplanted immediately after their blood test and could be monitored for subsequent infection risk, 13 (29.5%) experienced a pre-transplant infection a median 20 d (range 2-182) post-test. QFM < 214 IU/mL was associated with HR = 4.1 (P = 0.01) for infection. A very low QFM < 30 IU/mL was significantly associated (P = 0.003) with death in three patients who died while awaiting transplantation (HR = 56.6). CONCLUSION: QFM is lower in cirrhotics, allowing objective determinations of an individual’s unique level of immune dysfunction. Low QFM was associated with increased susceptibility to infection.
format Online
Article
Text
id pubmed-5165271
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-51652712017-01-03 Immune function biomarker QuantiFERON-monitor is associated with infection risk in cirrhotic patients Sood, Siddharth Yu, Lijia Visvanathan, Kumar Angus, Peter William Gow, Paul John Testro, Adam Gareth World J Hepatol Prospective Study AIM: To investigate whether a novel immune function biomarker QuantiFERON-Monitor (QFM) can identify cirrhotic patients at greatest risk of infection. METHODS: Adult cirrhotic patients on the liver transplant waiting list were recruited for this observational cohort study from a tertiary liver transplant referral unit. The immune function biomarker, QFM was performed using the same method as the widely available Quantiferon-gold assay, and measures output in interferon gamma in IU/mL after dual stimulation of the innate and adaptive immune systems. Ninety-one cirrhotic patients were recruited, with 47 (52%) transplanted on the day of their QFM. The remaining 44 (48%) were monitored for infections until transplant, death, or census date of 1(st) February 2014. RESULTS: Cirrhotic patients express a median QFM significantly lower than healthy controls (94.5 IU/mL vs 423 IU/mL), demonstrating that they are severely immunosuppressed. Several factors including model for end stage liver disease, presence of hepatocellular carcinoma, bilirubin, international normalized ratio and haemoglobin were associated with QFM on univariate analysis. Disease aetiology did not appear to impact QFM. On multivariate analysis, only Child-Pugh score and urea were significantly associated with a patient’s immune function as objectively measured by QFM. In the 44 patients who were not transplanted immediately after their blood test and could be monitored for subsequent infection risk, 13 (29.5%) experienced a pre-transplant infection a median 20 d (range 2-182) post-test. QFM < 214 IU/mL was associated with HR = 4.1 (P = 0.01) for infection. A very low QFM < 30 IU/mL was significantly associated (P = 0.003) with death in three patients who died while awaiting transplantation (HR = 56.6). CONCLUSION: QFM is lower in cirrhotics, allowing objective determinations of an individual’s unique level of immune dysfunction. Low QFM was associated with increased susceptibility to infection. Baishideng Publishing Group Inc 2016-12-18 2016-12-18 /pmc/articles/PMC5165271/ /pubmed/28050238 http://dx.doi.org/10.4254/wjh.v8.i35.1569 Text en ©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved. http://creativecommons.org/licenses/by-nc/4.0/ This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.
spellingShingle Prospective Study
Sood, Siddharth
Yu, Lijia
Visvanathan, Kumar
Angus, Peter William
Gow, Paul John
Testro, Adam Gareth
Immune function biomarker QuantiFERON-monitor is associated with infection risk in cirrhotic patients
title Immune function biomarker QuantiFERON-monitor is associated with infection risk in cirrhotic patients
title_full Immune function biomarker QuantiFERON-monitor is associated with infection risk in cirrhotic patients
title_fullStr Immune function biomarker QuantiFERON-monitor is associated with infection risk in cirrhotic patients
title_full_unstemmed Immune function biomarker QuantiFERON-monitor is associated with infection risk in cirrhotic patients
title_short Immune function biomarker QuantiFERON-monitor is associated with infection risk in cirrhotic patients
title_sort immune function biomarker quantiferon-monitor is associated with infection risk in cirrhotic patients
topic Prospective Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5165271/
https://www.ncbi.nlm.nih.gov/pubmed/28050238
http://dx.doi.org/10.4254/wjh.v8.i35.1569
work_keys_str_mv AT soodsiddharth immunefunctionbiomarkerquantiferonmonitorisassociatedwithinfectionriskincirrhoticpatients
AT yulijia immunefunctionbiomarkerquantiferonmonitorisassociatedwithinfectionriskincirrhoticpatients
AT visvanathankumar immunefunctionbiomarkerquantiferonmonitorisassociatedwithinfectionriskincirrhoticpatients
AT anguspeterwilliam immunefunctionbiomarkerquantiferonmonitorisassociatedwithinfectionriskincirrhoticpatients
AT gowpauljohn immunefunctionbiomarkerquantiferonmonitorisassociatedwithinfectionriskincirrhoticpatients
AT testroadamgareth immunefunctionbiomarkerquantiferonmonitorisassociatedwithinfectionriskincirrhoticpatients